上海美迪西生物医药股份有限公司（以下简称"公司"）第三届监事会第二 十二次会议于 2024 年 12 月 13 日以通讯方式召开。本次会议的通知已于 2024 年 12 月 9 日以电子邮件方式送达全体监事。本次会议由监事会主席曾宪成先生 召集并主持，应出席会议监事 3 人，实际出席会议监事 3 人。本次会议的召集、 召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、行政 法规以及《公司章程》的相关规定，会议合法有效。 二、监事会会议审议情况 会议经与会监事审议并书面表决通过了如下议案： (一)审议通过《关于作废部分已授予尚未归属的 2020 年限制性股票的议案》 证券代码：688202 证券简称：美迪西 公告编号：2024-056 本次作废部分已授予尚未归属的限制性股票符合《公司法》《中华人民共和 国证券法》《上市公司股权激励管理办法》《上海证券交易所科创板股票上市规则》 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等法律、法规及 公司 2020 年限制性股票激励计划的相关规定，不存在损害股东利益的情形。因 此，我们同意公司此次作废部分已授予尚未归属的限制性股票。 上海美迪西 ...

证券代码：688202 证券简称：美迪西 上海美迪西生物医药股份有限公司 投资者关系活动记录表 编号：2024-12-001~003 | --- | --- | --- | |----------------|------------------------------|------------------------------------| | | | 特定对象调研 £分析师会议 | | 投资者关系活动 | □ 媒体采访 £业绩说明会 | | | 类别 | □新闻发布会 £路演活动 | | | | £ | 现场参观 £其他（电话会议） | | | 2024 年 12 月 10 | 日： | | | 财通证券、国投瑞银、南土资产 | | | | 2024 年 12 月 10 | 日： | | 参与单位名称 | 中泰证券 | | | | 2024 年 12 月 11 | 日： | | | 华西证券 | | | 时间 | 2024 年 12 月 10 | 日、 2024 年 12 月 11 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：薛超 | | | --- | --- | | ...

证券代码：688202 证券简称：美迪西 公告编号：2024-054 上海美迪西生物医药股份有限公司 关于董事会、监事会延期换届的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海美迪西生物医药股份有限公司（以下简称"公司"）第三届董事会、第 三届监事会任期将于 2024 年 11 月 21 日届满。鉴于公司新一届董事会、监事会 的换届工作尚在积极筹备中，为保证董事会和监事会相关工作的连续性和稳定性， 公司董事会、监事会换届选举将延期进行，同时董事会各专门委员会委员、高级 管理人员的任期亦相应顺延。 在换届选举工作完成前，公司第三届董事会、第三届监事会全体成员、董事 会各专门委员会成员及高级管理人员将依照相关法律法规和《上海美迪西生物医 药股份有限公司章程》等有关规定，继续履行董事、监事、董事会各专门委员会 成员及高级管理人员的职责和义务。 本次延期换届不会影响公司的正常运营。公司将积极推进相关工作进程，尽 快完成换届选举，并及时履行信息披露义务。 特此公告。 上海美迪西生物医药股份有限公司董事会 2024 ...

Group 1: Financial Performance and Market Presence - In the first three quarters of 2024, revenue from overseas clients accounted for approximately 36% of the company's main business income, with a year-on-year increase in overseas orders [3] - The company aims to gradually increase its overseas business share to 40-50% to provide new growth directions [4] - The company has completed 490 new drug and generic drug projects from 2015 to June 2024, which have entered clinical trials through NMPA, FDA, and TGA approvals [5] Group 2: Research and Development Capabilities - The company has established a comprehensive preclinical new drug development capability and has a strong market position in the CRO industry [5] - It has developed over 440 tumor models and provides research services for major international oncology companies [6] - The company is leveraging AI technology to innovate drug discovery and optimize the R&D process [4] Group 3: Talent Acquisition and Management - As of the first half of 2024, 81.78% of employees hold a bachelor's degree or higher, with 29.32% holding master's or doctoral degrees [8] - The company is actively recruiting top talent, including positions such as COO, CSDO, and CTO, to enhance future development [8] - There is a focus on internal talent development and organizational efficiency to meet business growth needs [9]

Summary of Shanghai Medicilon's Conference Call Company Overview - Shanghai Medicilon Biopharmaceutical Co., Ltd. was established on February 2, 2004, and as of June 2024, the company has over 2,400 employees and laboratory space exceeding 84,000 square meters. The main business includes preclinical research for new drug development, covering drug discovery, pharmaceutical research, and preclinical studies [3]. Financial Performance - In the first three quarters of 2024, Medicilon's revenue decreased by 32.24% year-on-year, with a net loss attributable to shareholders of 129 million yuan, primarily due to changes in the biopharmaceutical investment environment, intensified industry competition, and declining order prices [2][4]. - For Q3 2024, the company reported revenue of 280 million yuan, a year-on-year decline of 9.83%. From January to September 2024, total revenue was 802 million yuan, with net losses of 58.44 million yuan and 60 million yuan for net profit and net profit excluding non-recurring items, respectively, reflecting declines of 211.99% and 241.90% [4]. Globalization Strategy - Medicilon has made significant progress in its globalization strategy, with the second research center in Boston now operational. This facility can provide various animal model services, including 440 tumor models and 250 non-tumor models, as well as pharmacokinetic evaluations that meet FDA standards [5]. Technological Advancements - The analysis and testing center in Shanghai has received CNAS certification, becoming a nationally recognized laboratory. This enables the company to offer integrated business analysis solutions and technical services [6]. - Medicilon has established strategic collaborations with Hengrun Pharmaceutical and Shanghai Gaobo Tumor Hospital to enhance innovation in small nucleic acid and gene cell therapy [6]. One-Stop R&D Service Platform - Medicilon is one of the few companies in China that provides a comprehensive one-stop new drug R&D service platform, covering the entire process from project discovery to preclinical research. The company has participated in and completed 490 new drug and generic drug projects, with approvals from NMPA, FDA, and TGA for clinical trials [7]. Talent Development - As of mid-2024, 82% of Medicilon's employees hold at least a bachelor's degree, with 29.32% holding master's or doctoral degrees. The proportion of R&D personnel is 85.71%, indicating a continuous optimization of the talent structure [8]. Future Development Strategy - Medicilon plans to enhance its R&D service levels and expand GMP experimental projects. The company aims to strengthen its capabilities in nucleic acid business, gene evaluation platforms, and AI-driven innovation platforms. Additionally, there will be an increased focus on overseas market expansion and improving management structures to enhance operational efficiency [9].

证券代码：688202 证券简称：美迪西 上海美迪西生物医药股份有限公司 投资者关系活动记录表 编号：2024-11-002 | --- | --- | --- | |----------------|--------------------------|----------------------------------------------------| | | | 特定对象调研 £分析师会议 | | 投资者关系活动 | □ | 媒体采访 £业绩说明会 | | 类别 | □新闻发布会 £路演活动 | | | | £ | 现场参观 £其他（电话会议） | | 参与单位名称 | | 兴业证券、中银资管、国泰基金、君和资本、南华基金、 | | | 工银安盛、海通创新 | | | 时间 | 2024 年 11 月 | 14 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：薛超 | | | 员姓名 | 证券办公室：卓楠、翁少凡 | | | 投资者关系活动 | 1 | 、问题：公司海外业务的拓展情况？ | | 主要内容介绍 | | 回答：公司在美国、欧洲、亚太地区等海外产业核心区 | ...

证券代码：688202 证券简称：美迪西 公告编号：2024-053 上海美迪西生物医药股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 三、 参加人员 投资者可于 2024 年 11 月 11 日(星期一)至 11 月 15 日(星期五)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 IR@medicilon.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海美迪西生物医药股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 11 月 18 日上午 10:00- 11:30 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频录 ...

证券代码：688202 证券简称：美迪西 上海美迪西生物医药股份有限公司 投资者关系活动记录表 编号：2024-11-001 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------| | | | 特定对象调研 £分析师会议 | | 投资者关系活动 | □ | 媒体采访 £业绩说明会 | | 类别 | □新闻发布会 £路演活动 | | | | £ | 现场参观 £其他（电话会议） | | 参与单位名称 | 长江证券、西部证券、和谐汇一 | | | 时间 | 2024 年 11 月 4 日 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：薛超 | | | 员姓名 | 证券办公室：卓楠、翁少凡 | | | 投资者关系活动 | 1 | 、问题：公司海外业务的拓展规划？ | | 主要内容介绍 | | 回答：公司在美国、欧洲、亚太地区等海外产业核心区 | | | | 域多点布局，加强实验室能力以及商务团队的 ...

Group 1: Company Overview - MediXis was established in 2004 as a comprehensive CRO providing clinical research services for global pharmaceutical companies and research institutions [2] - The company reported a revenue of CNY 802 million for the first three quarters of 2024, a decline attributed to changes in the biopharmaceutical investment environment and increased competition [2] - The net profit attributable to shareholders was CNY -129 million, reflecting a decrease due to intensified competition and reduced revenue [2] Group 2: Business Expansion and Strategy - The company has established a presence in key overseas markets, including the US, Europe, and the Asia-Pacific region, with a focus on enhancing laboratory capabilities and business development teams [3] - Approximately 36% of the company's main business revenue came from overseas clients in the first three quarters of 2024, with overseas orders showing year-on-year growth [3] - The Boston laboratory aims to increase the share of overseas business to 40-50%, supporting the growing demands of international clients [4] Group 3: Cost Reduction and Efficiency Improvement - The company plans to optimize its management structure and enhance operational efficiency through refined management practices and digital transformation [5] - Specific measures include integrated management of procurement, inventory, research, and financial operations to drive cost reduction [5] - Continuous assessment of R&D personnel and project needs will be conducted to align talent structure with business development [5] Group 4: Regulatory and Market Environment - The company views recent national policies supporting innovative drug development as beneficial for the industry and its future growth [6] - In the first half of 2024, the company participated in the development of 65 new drug and generic drug projects that received NMPA approval for clinical trials [6][7] Group 5: Technological Development - MediXis is focusing on building innovative research platforms, including those for nucleic acid drugs and AI-based preclinical research services [8] - The company has successfully completed preclinical research for numerous ADC drugs, with 28 approvals obtained [8] - Ongoing investments in technology innovation aim to enhance the company's R&D capabilities and competitive advantage [8]

Financial Performance - Revenue for Q3 2024 was CNY 280,304,304.26, a decrease of 9.83% compared to the same period last year[2] - Net profit attributable to shareholders was a loss of CNY 58,444,798.70, representing a decrease of 211.99% year-to-date[2] - Basic earnings per share for the year-to-date period was -CNY 0.96, a decrease of 203.23% compared to the same period last year[2] - The net profit for Q3 2024 was -128,675,088.23 RMB, a significant decline compared to the net profit of 114,900,869.11 RMB in Q3 2023[16] - The total profit for Q3 2024 was -161,891,596.84 RMB, compared to a profit of 119,347,196.63 RMB in the same period last year[16] - Operating profit for Q3 2024 was -160,506,352.85 RMB, a decrease from the operating profit of 119,659,284.83 RMB in Q3 2023[16] - Total operating revenue for the first three quarters of 2024 was ¥801,725,512.27, a decrease of 32.2% compared to ¥1,183,189,967.59 in the same period of 2023[14] - Total operating costs for the first three quarters of 2024 were ¥956,515,797.05, down from ¥1,065,803,867.08 in 2023, reflecting a reduction of 10.3%[14] Research and Development - R&D expenses totaled CNY 23,614,143.03 in Q3 2024, down 31.98% year-over-year[3] - The ratio of R&D expenses to revenue was 8.42%, a decrease of 2.75 percentage points compared to the previous year[3] - Research and development expenses for the first three quarters of 2024 amounted to ¥71,732,427.38, a decrease of 25.1% from ¥95,896,672.67 in the previous year[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,948,181,433.05, a decrease of 9.73% from the end of the previous year[3] - The company's total assets decreased to ¥2,948,181,433.05 in Q3 2024 from ¥3,265,847,480.54 in Q3 2023, representing a decline of 9.7%[13] - Total liabilities decreased to ¥596,326,012.22 in Q3 2024 from ¥755,068,116.91 in Q3 2023, a reduction of 21.1%[12] - The company's equity attributable to shareholders decreased to ¥2,351,855,420.83 in Q3 2024 from ¥2,510,779,363.63 in Q3 2023, a decrease of 6.3%[12] Cash Flow - Cash flow from operating activities was not applicable for the current period, with a year-to-date net cash flow of -CNY 68,749,348.95[2] - Cash flow from operating activities for the first three quarters of 2024 was -68,749,348.95 RMB, compared to -8,769,008.62 RMB in the same period of 2023[19] - Cash inflow from investment activities in Q3 2024 was 911,170,983.35 RMB, up from 426,713,927.73 RMB in Q3 2023[19] - Cash outflow from investment activities for Q3 2024 was 825,734,294.67 RMB, compared to 1,241,850,264.50 RMB in Q3 2023[19] - The net cash flow from financing activities for Q3 2024 was -128,771,566.61 RMB, a decrease from 1,158,070,037.64 RMB in Q3 2023[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,096[8] - The largest shareholder, Chen Jinzhan, holds 16,362,811 shares, representing 12.15% of total shares[9] Other Financial Metrics - Non-recurring gains and losses for the current period amounted to CNY 3,780,629.77, with a year-to-date total of CNY 13,152,699.47[5] - Cash and cash equivalents as of September 30, 2024, amount to ¥362,306,656.92, down from ¥471,870,185.67 at the end of 2023[10] - Accounts receivable increased to ¥644,574,473.01 from ¥591,002,959.52 year-over-year[10] - Inventory decreased to ¥109,102,073.10 from ¥165,518,376.11 year-over-year[10] - Total trading financial assets decreased to ¥292,579,561.49 from ¥518,231,957.07 year-over-year[10] - Other receivables increased significantly to ¥19,073,261.54 from ¥3,051,113.46 year-over-year[10] - Deferred tax assets increased significantly to ¥33,874,433.15 in Q3 2024 from ¥4,774,606.71 in Q3 2023, reflecting a growth of 610.5%[12] Operational Conditions - The company experienced a significant decline in revenue due to changes in the financing environment and intensified competition in the biopharmaceutical industry[6] - The company has not reported any significant changes in operational conditions during the reporting period[10] - The company has not issued any new guidance or outlook for future performance in this report[10]